MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
BMY stock logo

BMY

Bristol-Myers Squibb Company

$59.6
-2.13
 (-3.45%)
Exchange:  NYSE
Market Cap:  121.374B
Shares Outstanding:  2.136B
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Christopher S. Boerner
Full Time Employees:  34100
Address: 
Route 206 & Province Line Road
Princeton
NJ
8543
US
Website:  https://www.bms.com
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/02/05 — 4 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue45,006,00048,300,00048,194,000
Gross Profit25,357,00027,432,00032,602,000
EBITDA19,366,0003,168,00014,545,000
Operating Income8,472,0009,658,00012,696,000
Net Income8,025,000-8,948,0007,053,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets95,159,00092,603,00090,038,000
Total Liabilities65,674,00076,215,00071,532,000
Total Stockholders Equity29,430,00016,335,00018,473,000
Total Debt41,464,00051,200,00048,965,000
Cash and Cash Equivalents11,464,00010,346,00010,209,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow13,860,00015,190,00014,156,000
Capital Expenditure-1,209,000-1,248,000-1,311,000
Free Cash Flow12,651,00013,942,00012,845,000
Net Income8,040,000-8,933,0007,055,000
Net Change in Cash2,194,000-1,172,000-137,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)35,502,748.574Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)37,043,720.441Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)36,393,839.096Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)11,700,396.563Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)12,208,244.058Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)11,994,067.135Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)9,640,214.484Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)10,188,304.624Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)9,957,161.374Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)5,812,813.630Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)6,065,114.723Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)5,958,710.591Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)4.880Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)4.990Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)4.720Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)11Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)3Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
48.3B  ?P/S
 (TTM)
: 
2.55
?Net Income
 (TTM)
: 
-8948000000  ?P/E
 (TTM)
: 
17.41
?Enterprise Value
 (TTM)
: 
159.781B  ?EV/FCF
 (TTM)
: 
12.44
?Dividend Yield
 (TTM)
: 
0.04  ?Payout Ratio
 (TTM)
: 
0.72
?ROE
 (TTM)
: 
0.39  ?ROIC
 (TTM)
: 
0.14
?Net Debt
 (TTM)
: 
40.341B  ?Debt/Equity
 (TTM)
: 
2.55
?P/B
 (TTM)
: 
6.65  ?Current Ratio
 (TTM)
: 
1.26

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
9.51Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates BMY intrinsic value between $77.34 – $101.21 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate BMY Intrinsic Value

Common questions about BMY valuation

Is BMY (BMY) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for BMY (BMY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is BMY a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BMY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is BMY’s P/E ratio?

You can see BMY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for BMY?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is BMY a good long-term investment?

Whether BMY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

BMY

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-3.45
Chart data temporarily unavailable.
Daily snapshot

Trading Metrics:

Open: —   Previous Close: —
Day Low: —   Day High: —
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 
Session data unavailable

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read